Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria

Summary

The primary objective of this study is to evaluate the effect of tezepelumab on improvement in the Urticaria Activity Score over 7 days (UAS7).

Timeline

Start

2021-04-15

Primary completion

2022-12-20

Completion

2023-04-13

Publications

• Background McLaren J, Chon Y, Gorski KS, Bernstein JA, Corren J, Hayama K, Jain V, Lima H, Sofen H, Ponnarambil S, Molfino NA, Maurer M. Tezepelumab for the treatment of chronic spontaneous urticaria: Results of the phase 2b INCEPTION study. J Allergy Clin Immunol. 2025 Jun;155(6):1945-1956. doi: 10.1016/j.jaci.2025.01.045. Epub 2025 Feb 14.

Drugs

Indications